Stocks
Cyteir Therapeutics, Inc.CYT
NASDAQHealthcareBiotechnology$3.02-2.27%
Price as of · delayed, not real-time
Focused on developing next-generation cancer therapies, this biotech firm specializes in DNA damage response inhibitors. Its lead candidate targets hematologic malignancies, attracting investor interest in its clinical-stage pipeline. The company's modest market cap reflects its pre-revenue status and the high-risk, high-reward nature of oncology drug development.
Market Cap: $108.7M52W Range: $1.65-$3.19
Congressional Interest in Cyteir Therapeutics, Inc. (CYT)
4 members of Congress have disclosed 9 trades in Cyteir Therapeutics, Inc. (CYT), a Healthcare company. The buy/sell breakdown shows 7 purchases versus 2 sales, indicating net buying interest from lawmakers. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
Total Disclosures
9
Unique Politicians
4
Buys
7
Sells
2
Who in Congress Is Trading CYT?
| Date | Politician | Type | Amount |
|---|---|---|---|
| 2015-08-05 | JAMES B. RENACCI | sell | $1K-$15K |
| 2015-04-27 | Ed Whitfield | buy | $1K-$15K |
| 2012-12-04 | Nick J. Rahall | sell | $6,941.14 |
| 2012-10-04 | Nick J. Rahall | buy | $6,426.10 |
| 2011-07-09 | MICHAEL T. MCCAUL | buy | $1K-$15K |
| 2011-03-05 | MICHAEL T. MCCAUL | buy | $1K-$15K |
| 2011-02-03 | MICHAEL T. MCCAUL | buy | $1K-$15K |
| 2010-10-12 | MICHAEL T. MCCAUL | buy | $1K-$15K |
| 2010-10-12 | MICHAEL T. MCCAUL | buy | $1K-$15K |